{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["399(10324)"],"submitter":["Costa Clemens SA"],"funding":["NIHR Oxford Biomedical Research Centre"],"pubmed_abstract":["Introduction
The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac) has been widely used in a two-dose schedule. We assessed whether a third dose of the homologous or a different vaccine could boost immune responses.Methods
RHH-001 is a phase 4, participant masked, two centre, safety and immunogenicity study of Brazilian adults (18 years and older) in São Paulo or Salvador who had received two doses of CoronaVac 6 months previously. The third heterologous dose was of either a recombinant adenoviral vectored vaccine (Ad26.COV2-S, Janssen), an mRNA vaccine (BNT162b2, Pfizer-BioNTech), or a recombinant adenoviral-vectored ChAdOx1 nCoV-19 vaccine (AZD1222, AstraZeneca), compared with a third homologous dose of CoronaVac. Participants were randomly assigned (5:6:5:"],"journal":["Lancet (London, England)"],"pagination":["521-529"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8782575"],"repository":["biostudies-literature"],"pubmed_title":["Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study."],"pmcid":["PMC8782575"],"pubmed_authors":["Valliji Z","de Nobrega MM","Dejnirattisai W","de Avila Mendonca RN","Bittaye M","Franco MM","Costa Clemens SA","Clemens R","Pollard AJ","Beveridge A","Liu X","Queiroz Oliveira IS","Mongkolsapaya J","Tejpal C","Supasa P","Vernon S","Woods D","de Freitas Souza BS","RHH-001 study team","Ramos Souza A","Martins Medrado CL","Mead G","Lambe T","Aley P","Voysey M","Gonzalez IGS","Park J","de Moraes Pinto MI","Cantrell L","Smith H","Felle S","Screaton GR","Almeida Mendes AV","Davies S","Muniz Martins T","Sanders H","Eldawi A","Weckx L","de Arruda Cordeiro Matos LJ","Silveira MBV","Bibi S","Ulaszewska M","da Guarda SNF","Salvador N","Mabette R","Fraga M"],"additional_accession":[]},"is_claimable":false,"name":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.","description":"Introduction
The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac) has been widely used in a two-dose schedule. We assessed whether a third dose of the homologous or a different vaccine could boost immune responses.Methods
RHH-001 is a phase 4, participant masked, two centre, safety and immunogenicity study of Brazilian adults (18 years and older) in São Paulo or Salvador who had received two doses of CoronaVac 6 months previously. The third heterologous dose was of either a recombinant adenoviral vectored vaccine (Ad26.COV2-S, Janssen), an mRNA vaccine (BNT162b2, Pfizer-BioNTech), or a recombinant adenoviral-vectored ChAdOx1 nCoV-19 vaccine (AZD1222, AstraZeneca), compared with a third homologous dose of CoronaVac. Participants were randomly assigned (5:6:5:","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-18T13:44:51.24Z","creation":"2022-02-11T16:04:20.041Z"},"accession":"S-EPMC8782575","cross_references":{"pubmed":["35074136"],"doi":["10.1016/S0140-6736(22)00094-0"]}}